People with severe asthma insured by BlueCross BlueShield of Illinois may soon face a new hurdle in accessing a treatment ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Blue Cross Blue Shield of Oklahoma (BCBS), including BCBS plans in states of Illinois, New Mexico, Texas and Montana, is ...

The Oklahoma Allergy and Asthma clinic is pushing back against proposed changes in coverage for asthma medications covered by ...

Diphenhydramine HCl 50mg/mL; for IV or IM inj. Asthma and lower respiratory disorders. Glaucoma. Hyperthyroidism. Hypertension. Cardiovascular disease. GI or urinary obstruction. Sodium-restricted ...

The European Medicines Agency’s CHMP regulatory committee gave a positive opinion to add a self-administration option for asthma injection Fasenra (benralizumab), based on a new delivery method ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

We're not talking about patients who can control their asthma with an inhaler or pills. These are patients whose condition is so severe that doctors judge that periodic injection treatments are ...